Tumour immune contexture and immune evasion in sporadic and Lynch syndrome-associated microsatellite unstable colorectal cancers

Read full text
Authors: Samantha Martin, Hanna Elomaa, Juha P. Väyrynen, Maarit Ahtiainen, Erkki‐Ville Wirta, Jan Böhm, Toni T. Seppälä, A. Ristimäki, Kyösti Tahkola, Anne Mattila, Selja Koskensalo, Laura Renkonen‐Sinisalo
+5 more Anna Lepistö, Jukka-Pekka Mecklin, Kimmo Palin, Kristiina Rajamäki, Lauri A. Aaltonen
Cited by: 4
References: 83

Abstract

BACKGROUND: The high mutational burden in microsatellite unstable colorectal cancers (MSI CRCs) results in high immunogenicity, yet response rates to immunotherapy vary, suggesting underlying heterogeneity of the tumour immune landscape. Here, our aims were (1) to characterise the immune cell infiltrate and immune evasion in MSI CRCs, (2) to correlate these with clinical and genomic features, and (3) to compare these between Lynch syndrome (LS) and sporadic MSI CRCs. METHOD: Immunohistochemistry was utilised to detect T cell and myeloid cell subsets. Whole-genome and RNA sequencing were utilised to analyse somatic variants, tumour clonality, neoantigen burden, antigen presentation, immune checkpoint expression, and consensus molecular subtypes. RESULTS: Our results revealed higher immune cell scores in LS tumours, depicting higher T cell infiltration, compared to sporadic tumours. Conversely, sporadic tumours displayed increased infiltration of protumorigenic M2-like macrophages and increased expression of immune checkpoints PDCD1LG2 and CD40LG. Across our MSI CRC cohort, high neoantigen burden was associated with low tumour clonality. CONCLUSIONS: Our findings reveal differences between sporadic MSI and LS tumours in T cell and myeloid immune cell landscapes, and in immune evasion. These differences may contribute to the variable immunotherapy responses among MSI CRC patients and are targetable by emerging therapeutic approaches.

Fields of Study & Subjects

Genetic factors in colorectal cancer Cancer Immunotherapy and Biomarkers Ferroptosis and cancer prognosis

Publication details

Journal / source
British Journal of Cancer
Publisher
Springer Science and Business Media LLC
Volume
134
Issue
7
Pages
1019–1030
Publication date
14 January 2026
Language
EN